UBS Analysts Give Teva Pharmaceutical Industries (TEVA) a $20.00 Price Target
UBS set a $20.00 target price on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Monday morning, thefly.com reports. The firm currently has a hold rating on the stock.
Several other analysts also recently weighed in on the company. Royal Bank of Canada set a $13.00 price target on Teva Pharmaceutical Industries and gave the stock a sell rating in a research note on Friday, December 15th. Deutsche Bank set a $20.00 price target on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Friday, December 15th. Credit Suisse Group upgraded Teva Pharmaceutical Industries from an underperform rating to a neutral rating and upped their price target for the stock from $8.00 to $20.00 in a research note on Friday, December 15th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an underweight rating to an equal weight rating and set a $18.00 price target on the stock in a research note on Friday, December 15th. Finally, BTIG Research upped their price target on Teva Pharmaceutical Industries to $20.00 in a research note on Friday, December 15th. Five equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $20.68.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $17.45 on Monday. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market capitalization of $18,186.40, a P/E ratio of 4.13 and a beta of 0.55. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Exane Derivatives bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth $571,000. Korea Investment CORP raised its holdings in Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after purchasing an additional 30,674 shares during the period. Financial Counselors Inc. raised its holdings in Teva Pharmaceutical Industries by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after purchasing an additional 7,571 shares during the period. Private Capital Management Inc. raised its holdings in Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after purchasing an additional 8,850 shares during the period. Finally, Lockheed Martin Investment Management Co. bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth $317,000. 51.98% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/21/ubs-analysts-give-teva-pharmaceutical-industries-teva-a-20-00-price-target.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.